Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares gapped up before the market opened on Wednesday . The stock had previously closed at $11.43, but opened at $11.89. Stoke Therapeutics shares last traded at $13.18, with a volume of 172,442 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on STOK. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Trading Up 12.2 %

The stock has a market capitalization of $679.61 million, a PE ratio of -6.28 and a beta of 0.95. The business’s 50 day moving average is $12.39 and its 200 day moving average is $13.75.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. This trade represents a 17.87 % decrease in their position. The disclosure for this sale can be found here. 11.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently modified their holdings of STOK. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at about $29,000. Nisa Investment Advisors LLC increased its holdings in shares of Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stoke Therapeutics during the 2nd quarter worth $123,000. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at about $160,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.